Articles by tag: hypereosinophilic-syndrome

Fasenra and HES: what FDA approval in 2026 means

FDA approved Fasenra for the treatment of hypereosinophilic syndrome. How benralizumab is better than analogues, and why this is a strategy shift for AstraZeneca. Learn the prospects.

Fasenra approved by FDA for treatment of hypereosinophilic syndrome

FDA approved Fasenra (benralizumab) for HES therapy. 65% reduction in exacerbation risk and steroid-sparing effect. Learn how this changes the biosimilar market.